Drug Profile
Research programme: antibacterials - Betabiotics
Latest Information Update: 16 Jul 2016
Price :
$50
*
At a glance
- Originator Betabiotics
- Class
- Mechanism of Action DNA-directed DNA polymerase inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- No development reported Bacterial infections
Most Recent Events
- 16 Jul 2016 No recent reports of development identified for preclinical development in Bacterial-infections in Australia
- 12 Dec 2006 Preclinical trials in Bacterial infections in Australia (unspecified route)